Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.

 

Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

New study examines the health benefits of blue corn

AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer's …

Merck drives business opportunities in the U.S. to foster innovation across all three business secto …

FDA grants Roche's cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional …

Study reveals yoga may help children with cancer

Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

Close to half of adults and one quarter of kids in the US regularly consume artificial sweeteners

Bristol-Myers Squibb and GeneCentric Diagnostics announce exploratory biomarker research collaborati …

Channel Preference versus Promotional Reality: the core challenge of multichannel marketing

Novo Nordisk and Glooko partner to develop digital health solutions for people with diabetes

Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underly …

11th World Affordable Medicine Congress

Bristol-Myers Squibb announces immunotherapy clinical collaboration with Janssen

Sanofi and Boehringer Ingelheim confirm Closing of business swap

Vaccine shows promising results for early-stage breast cancer patients

This year’s JPM roundup: deals, lack of deals, a different breed of startup, and a Trump card

Patrick Soon-Shiong ‘met with Donald Trump’ for NIH chief job

Merck KGaA and Peter Thiel’s Palantir join forces to speed up R&D

Trump meets with tech leaders Srinivasan and O’Neill for FDA top job

Analyst says Celyad takes lead in CAR-T for solid tumors as THINK trial gets underway

Kitov buys program designed to stop cancer drug resistance

Nivalis axes CEO, 80% of staff after failed cystic fibrosis trial

Chutes & Ladders: John Kapoor retires from troubled Insys

JPM: 100 biopharma execs take gender-diversity pledge

CureVac's lead mRNA drug is down but not out, says CEO

Biogen spinout Bioverativ ‘not your normal upstart,’ says new chief

Ionis to get volanesorsen in front of the FDA ‘ASAP’: CEO

Merck KGaA pays $230M for four Vertex cancer programs

Alnylam shrugs off revusiran setback as new lead heads for phase 3 readout

Daiichi axes 170-person Indian R&D site

FDA consulting on 180-day generic exclusivity guidelines

OECD report warns of rising drug prices, urges new approach

Botox for depression? No need for furrowed brows, says Allergan’s head of R&D David Nicholson

Stroke risk for Alzheimer’s patients using certain tranquilizers, says Finnish study

Eisai buys rights to Rohypnol in Japan from Chugai and Roche

Pharma exports from Gujarat grow exponentially

Big pharma remains key to Europe’s economy, says independent report

India must protect innovators’ work product, says BIO chief

Dasotraline meets endpoint in adults with binge eating disorder but not ADHD

Kitov acquires fellow Israeli firm to enter immuno-oncology field

Latin America’s most modern women’s health products plant comes on stream

New Year's resolution for leadership in Australian life sciences innovation

Major Amendment to baricitinib NDA sets back FDA review three months

Upcoming OECD Health Ministerial to discuss healthcare systems – opportunities and challenges

Look back at pharma news to Jan 13

Medical News Today: Eating hot red chili peppers may help us live longer

Medical News Today: Dementia: Bilingualism may help brain conserve resources and resist decline

Medical News Today: Is Neurofeedback an Effective Treatment for ADHD?

Medical News Today: Why do older mothers have birth complications? New study investigates

Medical News Today: Just 20 minutes of exercise enough to reduce inflammation, study finds

Medical News Today: Natural Remedies for ADHD

Medical News Today: Early-Onset Alzheimer's: Symptoms, Diagnosis, and Treatment

Medical News Today: Sedentary behavior raises dementia risk as much as genetic factors

Medical News Today: Genital Psoriasis: Symptoms and Treatment

Medical News Today: Can chair yoga relieve osteoarthritis pain?

Medical News Today: Diet Tips for Multiple Sclerosis

Medical News Today: Can Biotin Help Treat Multiple Sclerosis?

Medical News Today: Just 45 minutes of exercise a week can benefit older adults with arthritis

Medical News Today: Musicians have faster reaction times

Medical News Today: What are the risks and benefits of cannabis use? New report sheds light

Trial to test fracture prevention combo in brittle bone patients

GPs not offering extended hours could face cash cuts

Sanofi licences ImmuNext autoimmune disease drug

FDA extends review time for Lillys’ RA drug

PharmaTimes Media announces the launch of the prestigious Sales Awards for 2017

Clinical researchers: gain visibility and recognition in your field

Clinical researchers in the Americas – could you win a coveted Pharma?

BIA knocks new plans for appraising rare disease therapies

NHS misses all major performance targets for November

UK’s Oxford Sciences Innovations partners with Celgene

Welsh gov’t brings in new bowel, cervical cancer tests

NICE recommends Novartis’ kidney cancer drug

EU approves Gilead’s hepatitis B therapy Vemlidy

Merck, Lilly to test new combo for soft tissue sarcoma

Doctors warn prime minister of threat to patient care

More News